A real-world pharmacovigilance study of cardiac adverse events induced by sugammadex in the FDA adverse event reporting system

This study suggests a potential link between sugammadex and CAEs, highlighting the need for careful monitoring and personalized risk assessment, especially in patients with cardiovascular risk factors.